^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/20/2020
Excerpt:
Osteosarcoma: Second-line therapy (relapsed/refractory or metastatic disease)…Other Recommended Regimens…Sorafenib + everolimus (category 2B)
